A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).

Ritu SalaniMary McCormackYong-Man KimSharad GhamandeShaundra L HallDomenica LorussoLisa BarracloughLucy GilbertAdrian Guzman RamirezChien-Hsing LuRenaud SabatierNicoletta ColomboYouyou HuVenkatesh KrishnanLuciana MolineroYuning FengNicole KimMarcela CastroYvonne G Lin Bradley J Monk

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)

The objective response rate with the tiragolumab-plus-atezolizumab combination was numerically higher than the historical reference but did not reach statistical significance.

Keyphrases

open label
placebo controlled
double blind
phase iii
phase ii
clinical trial
randomized controlled trial
study protocol